Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters

Article activity feed

1. Version published to 10.1128/jvi.01551-21

   Feb 23, 2022
2. 

   ScreenIT

   Jul 2, 2021

   SciScore for 10.1101/2021.06.29.450453: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IACUC: All experiments with hamsters were performed in accordance with the Science Council of Japan’s Guidelines for Proper Conduct of Animal Experiments.
   Sex as a biological variable	In brief, one-year-old male Syrian hamsters (Japan SLC Inc., Shizuoka, Japan) were enrolled.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   The amounts of SARS-CoV-2-S1-binding antibodies in each plasma sample were determined by using Anti-SARS-CoV-2 ELISA (IgG) (Euroimmun, Lübeck, Germany).	Anti-SARS-CoV-2 ELISA (IgG suggested: None
   The sections were treated with 5 % normal goat serum for 30 minutes at room …

   SciScore for 10.1101/2021.06.29.450453: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IACUC: All experiments with hamsters were performed in accordance with the Science Council of Japan’s Guidelines for Proper Conduct of Animal Experiments.
   Sex as a biological variable	In brief, one-year-old male Syrian hamsters (Japan SLC Inc., Shizuoka, Japan) were enrolled.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   The amounts of SARS-CoV-2-S1-binding antibodies in each plasma sample were determined by using Anti-SARS-CoV-2 ELISA (IgG) (Euroimmun, Lübeck, Germany).	Anti-SARS-CoV-2 ELISA (IgG suggested: None
   The sections were treated with 5 % normal goat serum for 30 minutes at room temperature and incubated with rabbit monoclonal anti SARS-CoV nucleoprotein antibody (Sino Biological, Beijing, China) at 4°C overnight.	anti SARS-CoV nucleoprotein suggested: None
   Detection and quantification of anti-SARS-CoV-2 IgG bound to viral components: The amounts of anti-SARS-CoV-2 IgG antibodies reactive with SARS-CoV-2 viral components in convalescent plasma were determined using the Simple Western Jess apparatus and the SARS-CoV-2 Multi-Antigen Serology Module (Protein Simple, San Jose, CA) according to the manufacturer’s instructions.	anti-SARS-CoV-2 IgG suggested: None SARS-CoV-2 Multi-Antigen Serology Module ( Protein Simple , San Jose , CA suggested: None
   Subsequently, the antibodies bound to the viral components were probed with horseradish peroxidase (HRP)-conjugated anti-human IgG (secondary antibody).	anti-human IgG suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Cells, viruses, and IgG purification: TMPRSS2-overexpressing VeroE6 (VeroE6TMPRSS2) cells (RRID: CVCL_YQ49) were obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, Japan).	VeroE6TMPRSS2 detected: (JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   The potency of SARS-CoV-2 inhibition by plasma or purified IgG was determined based on its inhibitory effect on virally induced cytopathicity in VeroE6TMPRSS2 cells.	VeroE6TMPRSS2 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   Software and Algorithms
   Sentences	Resources
   After scanning, the lung images were reconstructed by using the CosmoScan Database software (Rigaku Corporation) and analyzed as manufacturer’s instruction.	CosmoScan Database suggested: None
   For the viral titer in lung, each the convalescent plasma receiving group was compared with the healthy donor plasma receiving group using Dunnett’s test by using JMP Pro 15.0.0 (SAS Institute).	SAS Institute suggested: (Statistical Analysis System, RRID:SCR_008567)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   One limitation of the current study is that only one SARS-CoV-2 strain (SARS-CoV-205-2N) was employed and the results obtained here may not predict the efficacy in individuals infected with other SARS-CoV-2 strains, in particular, SARS-CoV-2 variants recently isolated38–41, which may escape neutralizing antibodies in plasmas used in the present study42 or may replicate more efficiently than previously isolated SARS-CoV-2 strains such as SARS-CoV-205-2N 43. However, if convalescent plasmas are collected from individuals who are infected with certain SARS-CoV-2 variants, the plasmas from such individuals should be of use to immediately treat others infected with the same variants. In conclusion, the present data strongly suggest that administering highly-neutralizing COVID-19-convalescent plasmas should be efficacious in treating patients with COVID-19, but potent neutralizing activity has to be confirmed before administering such convalescent plasmas.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.06.29.450453 on bioRxiv

   Jun 30, 2021